Please Wait...


Sarcopenia and Aging: ASBMR Annual Meeting Hot Topic

  • 0
  • 10 Jan
Late last year I attended the annual meeting of the American Society of Bone & Mineral Research (ASBMR) in Toronto. One of the hot topics was sarcopenia, a term which describes the process associated with muscle loss, something that occurs as we get older. The term is derived from greek roots, sarx (flesh) and penia (loss). A lot of research has taken place in osteoporosis and its prevention but sarcopenia has considerable clinical significance. Age-related reduction in muscle mass, function and strength leads to the reduced ability to undertake the physical activities of daily living together with an increased risk of fall and related injury. Loss of muscle mass is therefore associated with risk of fracture.
Read More

Are Placebo-Controlled Trials in Osteoporosis Ethical?

  • 0
  • 13 Oct
The New England Journal of Medicine has entered the debate around whether it is ethical to have placebo-controlled trials in osteoporosis. For those of us involved in clinical research in osteoporosis, this is a fascinating debate and reflects the challenge between the regulatory requirements and current ethical understanding, which are always intertwined. Placebo in this arena always consists of Vitamin D and Calcium supplementation, which have some bone sparing effects. However, there is a good range of therapies on the market with proven efficacy.
Read More
FRAX iPhone app screen shot – can be used in clinical trials

FRAX iPhone app Tool to Access Fracture Risk in Clinical Trials

  • 0
  • 19 May
The iPhone continues to make inroads into all aspects of our lives, and medical imaging and clinical trials have not escaped. Doctot (Doc tools of the trade), an Irish company run by medical and software professionals, recently launched an iPhone app (priced at $5.99 in the US), which makes the WHO Fracture Risk Assessment Tool (FRAX) readily accessible to doctors.
Read More


Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Removing Risk from #ClinicalTrial Management System (CTMS) Implementations @bioclinica
bioclinica (5 hours ago)
Our Research Dev. Director Marieke Cajal in a poster presentation at #CNS Summit showed, "How to Scale up Recruitme…
bioclinica (5 hours ago)
Great advice on imaging in #clinicaltrials!
bioclinica (3 days ago)
bioclinica (3 days ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica
bioclinica (3 days ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner…
bioclinica (3 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices